Young-Onset Breast Carcinoma Tends to Show a Higher Proportion of Triple-Negative Subtype: A Comparative Molecular and Pathological Analysis
Main Article Content
Introduction. Breast carcinoma in young women is often associated with more aggressive molecular profiles and suboptimal therapeutic responses. This study was designed to compare the molecular and histopathological characteristics of patients younger than 40 years with those aged 40 years and above. Methods. This study employed a retrospective descriptive-analytic design using clinical and pathological data from 36 patients diagnosed with invasive breast carcinoma. All cases were collected from the Department of Anatomical Pathology at Mohammad Hoesin General Hospital in Palembang, Indonesia, in 2023. Results. The molecular subtype profile was similarly distributed across the two age categories, with no statistically significant difference by age (p = 0.789). However, the younger cohort showed a relatively higher proportion of triple-negative cases. Luminal B remained the most prevalent molecular subtype in both groups. Likewise, ER, PR, and HER2 expression showed no significant differences according to age (p > 0.05). All patients exhibited high Ki-67 expression, and grade III was the predominant histological grade in both groups. Dominant TILs were observed in only a small fraction of cases, with no statistically significant age-related difference. Conclusion. Although younger patients showed a relative proportion of triple-negative cases and all tumors demonstrated high proliferative activity, no statistically significant differences in molecular subtype distribution or other clinicopathological parameters were identified between the two age groups. Luminal B remained the predominant molecular subtype in both groups. These findings suggest that age-related biological differences may exist, but larger studies are needed to clarify this association.
2. Johnson KS, Conant EF, Soo MS. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. J Breast Imaging. 2021;3(1):12–24.
3. Lamb CA, Vanzulli SI, Lanari C. Hormone receptors in breast cancer: More than estrogen receptors. Medicina (B Aires). 2019;79(6).
4. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20.
5. Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O’Shaughnessy JA, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024;391(22):2110–2122.
6. Menon G, Alkabban F, Ferguson T. Breast Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2025.
7. WHO. WHO Classification of Tumors Editorial Board. Breast Tumors. 5 th Editi. France: Lyon: International Agency of Research on Cancer; 2019.
8. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867-3872.
9. Liang Q, Ma D, Gao RF, Yu KD. Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes. Sci Rep. 2020;10(1):7648.
10. Nambiar K, Bal A. Pathology and molecular classification of breast cancer. In: Evidence in Breast Cancer. Springer; 2025.
11. Saeidi Y, Ghorbani M, Najafi A, Moghaddam MM. Identifying molecular determinants and therapeutic targets in luminal B breast cancer: a systems biology approach. Iran J Pathol. 2025;20(4):478–488.
12. Varzaru VB, Vlad T, Popescu R, Vlad CS, Moatar AE, Cobec IM. Triple-negative breast cancer: molecular particularities still a challenge. Diagnostics. 2024;14(17):1875.
13. Lee J, Lee YJ, Bae SJ, Baek SH, Kook Y, Cha YJ, Lee JW, Son BH, Ahn SH, Lee HJ, Gong G, Jeong J, Lee SB, Ahn SG. Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients with Breast Cancer. JAMA Netw Open. 2023;6(8):e2330961.
14. Wang C, Chen J, Lv X, Yun T, Wang Y, Meng N, et.al. Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world. BMC Cancer. 2025;25:962.
15. Dogra AK, Prakash A, Gupta S, Gupta M. Prognostic significance and molecular classification of triple-negative breast cancer: a systematic review. Eur J Breast Health. 2025;21(2):101–114.
16. Uddin MN, Wang X. Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer. Breast Cancer. 2022;29(3):541-561.
